Sanofi Group

Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
Sanofi P. aeruginosa Infectious Disease Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started

In September 2010, Pieris signed a multi-year, multi-target collaboration with both Sanofi (formerly Sanofi-Aventis) and Sanofi Pasteur across a broad spectrum of indications. In April 2013 the partnership was expanded to include a novel multispecific Anticalin® program under the existing framework of the 2010 agreement.

The lead program under this collaboration is currently in preclinical development.